Concepedia

Publication | Closed Access

PROPHYLACTIC ORAL GANCICLOVIR COMPARED WITH DEFERRED THERAPY FOR CONTROL OF CYTOMEGALOVIRUS IN RENAL TRANSPLANT RECIPIENTS1,2,???

DOI

155

Citations

7

References

1997

Year

Daniel C. Brennan, Kathy A. Garlock, Gary G. Singer, Mark A. Schnitzler, Bruce J. Lippmann, Richard S. Buller, Monique Gaudreault‐Keener, Jeffrey A. Lowell, Surendra Shenoy, Todd K. Howard,
Transplantation

Abstract

An initial 12-week course of oral ganciclovir prevents CMV disease and infection in renal transplant recipients during prophylaxis, and the benefits persist after discontinuation.

References

YearCitations

Page 1